ADC Therapeutics SA (ADCT)
NYSE: ADCT · Real-Time Price · USD
1.630
-0.040 (-2.40%)
Feb 21, 2025, 4:00 PM EST - Market closed
ADC Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADC Therapeutics stock have an average target of 8.00, with a low estimate of 6.00 and a high estimate of 10. The average target predicts an increase of 390.80% from the current stock price of 1.63.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 6, 2025.
Analyst Ratings
The average analyst rating for ADC Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +390.80% | Jan 6, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +513.50% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Dec 11, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $6 | Buy | Initiates | $6 | +268.10% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +390.80% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
74.30M
from 69.56M
Increased by 6.81%
Revenue Next Year
82.64M
from 74.30M
Increased by 11.23%
EPS This Year
-1.74
from -2.94
EPS Next Year
-1.57
from -1.74
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 77.5M | 91.4M | 149.6M | |||
| Avg | 74.3M | 82.6M | 115.5M | |||
| Low | 70.4M | 74.9M | 80.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.4% | 23.0% | 81.0% | |||
| Avg | 6.8% | 11.2% | 39.7% | |||
| Low | 1.2% | 0.8% | -2.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.47 | -1.21 | -0.90 |
| Avg | -1.74 | -1.57 | -1.20 |
| Low | -1.83 | -1.82 | -1.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.